AAIC 2018 | Synaptoprotective Sigma-2 antagonists for Alzheimer’s
The Sigma-2 receptor (Sig2R) is widely expressed throughout the central nervous system and has recently been implicated in the development of Alzheimer’s disease. In this interview, Susan Catalano, PhD, of Cognition Therapeutics Inc., Pittsburgh, PA, tells us about a novel drug her research group is developing that specifically targets Sig2R. Dr Catalano outlines the mechanism of action of this drug and its relevance to the development of Alzheimer’s. This interview took place at the 2018 Alzheimer’s Association International Conference (AAIC) 2018, held in Chicago, IL.
Get great new content delivered to your inboxSign up